AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22081616
Drug: L. barbarum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L. barbarum (120 ml daily for 14 days)
Trial: 15880608
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (peginterferon and lamivudine)
Trial: 14624818
Drug: Group comprehensive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group comprehensive cognitive behavioral therapy (CCBT)
Trial: 14624818
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of FLU and PLA
Trial: 2058823
Drug: Propofol 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2.5 mg/kg i.v. induction and 3-5 mg/kg per hour i.v. maintenance
Trial: 2058823
Drug: Thiopental 5
RxNorm normalized name: thiopental 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental 5 mg/kg i.v. induction and isoflurane 0.4-0.8 vol.% maintenance
Trial: 2058823
Drug: Etomidate 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate 0.2 mg/kg i.v. induction and flunitrazepam 0.005-0.01 mg/kg i.v. and fentanyl 0.0025-0.005 mg/kg i.v. bolus injections every 20-30 min maintenance
Trial: 6286118
Drug: PIVN-associated chemotherapy
RxNorm normalized name: HEPATITIS ASSOCIATED ANTIBODY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIVN-associated chemotherapy
Trial: 6276949
Drug: Chemotherapy control
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy control group
Trial: 6286118
Drug: PIVN-associated chemotherapy
RxNorm normalized name: HEPATITIS ASSOCIATED ANTIBODY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIVN-associated chemotherapy and chemotherapy control group
Trial: 22966839
Drug: Whole-body vibration
RxNorm normalized name: Insects (whole body), mite dermatophagoides farinae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-body vibration therapy (WBV) for 2 weeks, six 15-min sessions, 2 mm amplitude, 12 Hz frequency
Trial: 22966839
Drug: Whole-body vibration
RxNorm normalized name: Insects (whole body), mite dermatophagoides farinae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-body vibration therapy (WBV)
Trial: 17470020
Drug: Naproxen sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen sodium (275 mg daily for 6 weeks)
Trial: 15240605
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone (4.1 mg/patch, twice a week; estimated delivery rate, 150 microg/d)
Trial: 9615369
Drug: Ambulant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambulant chemotherapy
Trial: 8583218
Drug: Albendazole 800
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole 800 mg/day for 8 days
Trial: 8583218
Drug: Albendazole 800
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole 800 mg/day for 15 days
Trial: 8583218
Drug: Albendazole 800
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole 800 mg/day for 30 days
Trial: 2677294
Drug: Indomethacin (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (0.2 mg/kg intravenously at 6 hours of age and 0.1 mg/kg at 18 and 30 hours)
Trial: 26238866
Drug: Medication and
RxNorm normalized name: CVS Health Medication and Topical Refill Pouch KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication and Adherence Inventory
Trial: 16505505
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine 10 units/day
Trial: 15497664
Drug: Cefaclor 500
RxNorm normalized name: cefaclor 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor 500 mg capsules (Losefar 500 mg Capsules)
Trial: 15497664
Drug: Cefaclor 250
RxNorm normalized name: cefaclor 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor 250 mg/5 mL suspension (Losefar 250 mg/5 mL Granules oral suspension)
Trial: 15497664
Drug: Cefaclor (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor (both formulations)
Trial: 11266032
Drug: Parenteral vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral vitamin B12 (3 injections of 1 mg at 4-week intervals)
Trial: 22965772
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment group (10 solitary and 4 multiple tumors, neo-adjuvant CTX followed by response-adapted RT)
Trial: 22965772
Drug: RT-only treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT-only treatment group
Trial: 15292626
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment group
Trial: 20850812
Drug: Prazosin (0.025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (0.025 mg/kg nightly for 1 week, then increased to 2 divided doses)
Trial: 20850812
Drug: Placebo (nightly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (nightly for 1 week, then increased to 2 divided doses)
Trial: 9798830
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment plus whirlpool (Group B)
Trial: 9798830
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment only (Group A)
Trial: 8033762
Drug: Increased methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased methadone dose (50-80 mg)
Trial: 8033762
Drug: Decreased methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decreased methadone dose (80-50 mg)
Trial: 2500273
Drug: Standard intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intramuscular injections (25 mg/kg body weight every week after a 4-week loading phase of 50 mg/kg/week)
Trial: 2500273
Drug: Intravenous Intraglobin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Intraglobin F (300 mg/kg body weight every 3 weeks after initial treatment)
Trial: 17342169
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of clonidine and modafinil
Trial: 15538264
Drug: Sublingual apomorphine
RxNorm normalized name: apomorphine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual apomorphine (3 mg)
Trial: 15538264
Drug: Oral sildenafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sildenafil (50 mg)
Trial: 9481967
Drug: Topical anesthetic
RxNorm normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical anesthetic with vibration
Trial: 7575694
Drug: Tenidap 120
RxNorm normalized name: tenidap
DrugBank: Tenidap (DB13481)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenidap 120 mg/day
Trial: 3035913
Drug: Platinum (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum (60 mg/m2), doxorubicin (40 mg/m2), and VP-16 (150 mg/m2) (PAV)
Trial: 3035913
Drug: Platinum (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum (60 mg/m2), 4'-epidoxorubicin (50 mg/m2), and VP-16 (150 mg/m2) (PEV)
Trial: 24163364
Drug: Methylphenidate (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (0.5 mg/kg)
Trial: 11736883
Drug: Finrozole 3
RxNorm normalized name: Fadrozole
DrugBank: Fadrozole (DB16832)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finrozole 3 mg tablets
Trial: 11736883
Drug: Finrozole 9
RxNorm normalized name: Fadrozole
DrugBank: Fadrozole (DB16832)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finrozole 9 mg tablets
Trial: 11736883
Drug: Finrozole 30
RxNorm normalized name: Fadrozole
DrugBank: Fadrozole (DB16832)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finrozole 30 mg tablets
Trial: 11736883
Drug: Finrozole solution
RxNorm normalized name: Fadrozole
DrugBank: Fadrozole (DB16832)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finrozole solution (dosage not specified)
Trial: 11736883
Drug: Finrozole tablets
RxNorm normalized name: Fadrozole
DrugBank: Fadrozole (DB16832)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finrozole tablets (general)
Trial: 11736883
Drug: Finrozole 3
RxNorm normalized name: Fadrozole
DrugBank: Fadrozole (DB16832)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finrozole 3 mg tablets vs 9 mg tablets
Trial: 19491859
Drug: Placebo (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (twice daily for 8 weeks)
Trial: 23973688
Drug: simvastatin plus
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: simvastatin plus extended-release niacin (ERN, 1,500 to 2,000 mg/day)
Trial: 17308269
Drug: AC (doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AC (doxorubicin 54 mg/m2 and cyclophosphamide 1.2 g/m2 IV every 3 weeks for six cycles)
Trial: 17308269
Drug: A ->
RxNorm normalized name: I'm afraid I don't have enough information to determine the full generic name for the drug abbreviation "A ->". Drug abbreviations can vary and may not have a clear one-to-one mapping to a full generic name. Without more context about the specific drug or clinical trial, I cannot provide the full generic name. I apologize that I cannot give you a more definitive answer.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A -> C (doxorubicin 40.5 mg/m2 IV days 1 and 2 every 3 weeks for four cycles followed by cyclophosphamide 2.4 gm/m2 IV every 2 weeks for three cycles)
Trial: 19890256
Drug: Sibutramine 15
RxNorm normalized name: sibutramine 15 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine 15 mg daily
Trial: 9741602
Drug: Ultrasound (US)
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound (US) alone with an identical gel absent the steroid
Trial: 25159818
Drug: HDACi 109
RxNorm normalized name: Hdac-in-4
DrugBank: CXD101 (DB16182)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDACi 109 (RG2833) at doses ranging from 30mg/day to 240mg/day
Trial: 22023516
Drug: High-dose therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose therapy followed by autologous stem cell transplantation
Trial: 22023516
Drug: Complex karyotype,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex karyotype, translocation t(4;14), β(2)-microglobulin level > 2.5 mg/L
Trial: 16762371
Drug: Olanzapine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (up to 15 mg)
Trial: 10227322
Drug: Outer-membrane protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outer-membrane protein (OMP) meningococcal vaccine
Trial: 6638856
Drug: Cephradine prophylaxis
RxNorm normalized name: Cephradine
DrugBank: Cefradine (DB01333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cephradine prophylaxis (1 gram at induction of anaesthesia, followed by three postoperative doses of 1 gram at 6 hourly intervals)
Trial: 30705033
Drug: Aggressive dose
RxNorm normalized name: ZO SKIN HEALTH Aggressive Anti-Aging Program KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive dose escalation (group B)
Trial: 30705033
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose escalation (group A)
Trial: 19240522
Drug: Intraarticular sodium
RxNorm normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intraarticular sodium hyaluronate injections at weekly intervals for 3 weeks
Trial: 7564973
Drug: Water placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water placebo + 280 mg nicotinic acid.l‐1 (WP + NA)
Trial: 6927816
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg Ro 13-5057
Trial: 6927816
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg Ro 13-5057
Trial: 6927816
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg Ro 13-5057
Trial: 27734549
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine (2.5 mcg·kg‐1)
Trial: 27734549
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam (0.5 mg·kg‐1)
Trial: 21087463
Drug: Methylcellulose (bulking-agent)
RxNorm normalized name: Methylcellulose
DrugBank: Methylcellulose (DB11228)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylcellulose (bulking-agent)
Trial: 27156189
Drug: Azithromycin 10
RxNorm normalized name: azithromycin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 10 mg/kg once daily for 3 days
Trial: 30119284
Drug: Oral thyroxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral thyroxin (5 μg/kg) administered 12 hours before surgery and once daily during ICU stay
Trial: 22525511
Drug: Ultrasound Guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound Guided BC aspiration and corticosteroid injection (Group A)
Trial: 22525511
Drug: Horizontal Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Horizontal Therapy (Group B)
Trial: 22525511
Drug: Ultrasound Guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound Guided BC aspiration and corticosteroid injection plus Horizontal therapy (Group C)
Trial: 9311214
Drug: Lidocaine tape
RxNorm normalized name: lidocaine Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine tape applied to patients without preanesthetic medication (group N)
Trial: 9311214
Drug: Lidocaine tape
RxNorm normalized name: lidocaine Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine tape applied to patients who received 0.1 mg.kg‐1 of diazepam (group D)
Trial: 8346816
Drug: Ketorolac 30-60
RxNorm normalized name: ketorolac 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 30-60 mg IV
Trial: 8346816
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of fentanyl 50-100 micrograms and ketorolac 30-60 mg IV
Trial: 3787552
Drug: Isoprenaline (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoprenaline (400 microgram) given by inhalation after infusion
Trial: 31559638
Drug: CGRP monoclonal
RxNorm normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGRP monoclonal antibodies (mAbs)
Trial: 30486868
Drug: Current standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current standard in obesity treatment
Trial: 25186159
Drug: Multiple daily
RxNorm normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple daily injections for 2 years
Trial: 19290686
Drug: Low-dose beverage
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose beverage (target blood alcohol level = .04)
Trial: 19290686
Drug: High-dose beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose beverage (target blood alcohol level = .08)
Trial: 12351250
Drug: Propacetamol 2
RxNorm normalized name: 1,2,3-PROPANETRIOL, 2-(4-AMINOBENZOATE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propacetamol 2 g IV every 6 hours for 72 hours
Trial: 9440727
Drug: Epirubicin (EPI)
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epirubicin (EPI) 160 mg/m2 I.V. every 3 weeks
Trial: 9440727
Drug: Epirubicin (EPI)
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epirubicin (EPI) 160 mg/m2 I.V. every 3 weeks with DEX 1,000 mg/m2 I.V.
Trial: 7985637
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg beta-carotene/d
Trial: 2656087
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of mifepristone + 0.5 mg gemeprost vaginal pessary
Trial: 2656087
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of mifepristone + 1 mg gemeprost vaginal pessary
Trial: 29151374
Drug: MDG oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDG oil with 6 mg lutein (FloraGLO 20%)
Trial: 3522894
Drug: Vidarabine 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vidarabine 15 or 30 mg/kg/day
Trial: 27532780
Drug: Low-concentration fish
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-concentration fish sauce (2 g/L)
Trial: 27532780
Drug: High-concentration fish
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-concentration fish sauce (8 g/L)
Trial: 18201872
Drug: Topical retinoic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical retinoic acid (0.025%) treatment
Trial: 23169946
Drug: Estrogen plus
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen plus progestin (0.625 mg/d conjugated equine estrogens plus 2.5 mg/d medroxyprogesterone acetate)
Trial: 6219964
Drug: Topical 1%
RxNorm normalized name: fluoride topical 1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1% clindamycin phosphate combined with tretinoin gel 0.025%
Trial: 6219964
Drug: Topical 1%
RxNorm normalized name: fluoride topical 1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1% clindamycin phosphate alone
Trial: 6219964
Drug: Tretinoin gel
RxNorm normalized name: Tretinoin Gel
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tretinoin gel 0.025% alone
Trial: 31697990
Drug: Stereotactic ablative
RxNorm normalized name: ABL
DrugBank: Lauric acid (DB03017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic ablative radiation therapy (SAbR) boost, 28 Gy in 4 fractions
Trial: 23571179
Drug: HBsAg‐1018 (investigational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBsAg‐1018 (investigational hepatitis B surface antigen vaccine with phosphorothioate oligodeoxyribonucleotide adjuvant)
Trial: 23571179
Drug: HBsAg‐Eng (commercially
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBsAg‐Eng (commercially available, alum‐adjuvanted hepatitis B vaccine)
Trial: 21228629
Drug: RIX4414 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIX4414 vaccine stored at 2°C‐8°C (Group RIX4414-control)
Trial: 21228629
Drug: RIX4414 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIX4414 vaccine stored at 37°C for 7 days (Group RIX4414-37°C)
Trial: 22042952
Drug: 6 months
RxNorm normalized name: leuprolide 45 mg/6 months intramuscular kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 months of androgen suppression therapy (AST)
Trial: 17557956
Drug: 3 months
RxNorm normalized name: TABLET, DOSE PACK, 3 MONTHS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 months of androgen suppression therapy (AST)
Trial: 11942874
Drug: Metoclopramide 10
RxNorm normalized name: metoclopramide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 10 mg (Group M10)
Trial: 11942874
Drug: Metoclopramide 20
RxNorm normalized name: metoclopramide 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 20 mg (Group M20)
Trial: 9556321
Drug: High-calorie, high-protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-calorie, high-protein diet plus protein hydrolysate (70 g/day) for Group 2 patients (n = 7)
Trial: 333644
Drug: Methylprednisolone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (5 grams intravenously administered 2-4 hours prior to organ harvesting)
Trial: 7270725
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g of gluten daily for 5 weeks
Trial: 30300282
Drug: 24-hour urinary
RxNorm normalized name: Urinary hCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-hour urinary creatinine excretion, TIMP‐2/mOsm, and total warm ischemia time on day 10
Trial: 20961701
Drug: Perifracture site
RxNorm normalized name: SOLO SITE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perifracture site injection (PI) with local anesthetic mixture (ropivacaine, morphine, epinephrine); n = 22.
Trial: 20961701
Drug: No perifracture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No perifracture site injection (no-PI); n = 22.
Trial: 12736155
Drug: l-arginine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-arginine (1 g/min for 30 min) with insulin (6 mU x kg(‐1) x min(‐1) for 120 min)
Trial: 12736155
Drug: l-arginine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-arginine (1 g/min for 30 min) without insulin